$ cat ./records/gates-foundation-awards-path-27-8-million-for-hpv-vaccine-demonst-2006.txt
Gates Foundation Awards PATH $27.8 Million for HPV Vaccine Demonstration Programs in Four Countries
[RECORD.TXT] · cat --full
The Gates Foundation awarded PATH a five-year, $27.8 million grant to conduct HPV vaccine demonstration programs in India, Peru, Uganda, and Vietnam. The project generated the evidence base governments in low-income countries needed to introduce HPV vaccines and developed delivery strategies for reaching adolescent girls without schools-based health infrastructure. GSK and Merck provided vaccines for the demonstration projects, which were the first large-scale HPV vaccination programs outside high-income countries.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Awards $46.7 Million to Integrate Five Neglected Tropical Disease Programs
Next →
Gates Foundation Funds Drought-Tolerant Maize Programme Across 13 African Countries
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.